



Nevada PEBP

Q2 FY2024

Prepared by Client Analytics

Cynthia Eaton (cynthia.eaton@express-scripts.com)

3/15/2024



**The data contained herein is pulled from a specific point-in-time and is subject to change at any time without notice due to a variety of factors, including but not limited to changes related to Member behavior, population demographics, system updates, and product availability. The data does not represent a guarantee and should not be used for audit purposes.*

Hello PEBP Team,

This is the Q2 FY24 Summary File for the three State of Nevada PEBP plans (CDHP, EPO, and PPO). The summary contains Trend breakouts for each plan (Utilization, Unit Cost, and Cost Share). Along with the most notable changes of drugs within the top moving indications. Each plan breakout has a peer comparison of Trend. The file concludes with several Key Statistics of the three plans in aggregate.

CDHP Overall Trend Summaries:

| CDHP Overall Trend | | % Change |
|---|----------------|-----------------|
| Current Period - Plan Cost Net PMPM | \$73.39 | |
| Utilization | \$2.15 | 3.2% |
| Unit Cost | \$3.83 | 5.7% |
| Member Share | \$0.12 | 0.2% |
| Total Change in Plan Cost Net PMPM | \$6.10 | 9.1% |
| Previous Period - Plan Cost Net PMPM | \$67.29 | |

Top moving indications and most notable drug changes within the indications are as follows:

- **Cancer:**
 - Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↓ \$539k (-24.1%) to current \$1.7m.
 - Plan Cost Net PMPM ↓ \$1.66 (-12.5%) to current \$11.66.
 - Patient Count ↓ 4 to current count of 196.
 - Adjusted Rxs ↓ 73 to current count of 922.
- **Notable Drug Changes within Indication:**
 - **Lenalidomide (Generic for Revlimid)**
 - Previous ranked 15th, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$203k (785.5%) to current \$229k.
 - Plan Cost Net PMPM ↑ \$1.42 (920.8%) to current \$1.57.
 - Patient Count ↑ 2 to current count of 3.
 - Adjusted Rxs ↑ 16 to current count of 18.
 - **Ibrance**
 - Previous ranked 2nd, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↓ \$176k (-60.2%) to current \$116k.
 - Plan Cost Net PMPM ↓ \$.94 (-54.2%) to current \$.80.
 - Patient Count ↓ 2 to current count of 2.
 - Adjusted Rxs ↓ 14 to current count of 8.
 - **Revlimid**
 - Previous ranked 1st, currently ranked 9th by Plan Cost Net.
 - Plan Cost Net ↓ \$284k (-77.8%) to current \$81k.
 - Plan Cost Net PMPM ↓ \$1.62 (-74.4%) to current \$.55.
 - Patient Count ↓ 2 to current count of 2.
 - Adjusted Rxs ↓ 16 to current count of 7.

- **Ophthalmic Conditions:**
 - Previous ranked 20th, currently ranked 6th by Plan Cost Net.
 - Plan Cost Net ↑ \$385k (311.4%) to current \$508k.
 - Plan Cost Net PMPM ↑ \$2.75 (374.3%) to current \$3.49.
 - Patient Count ↑ 17 to current count of 218.
 - Adjusted Rxs ↑ 6 to current count of 449.

- **Notable Drug Changes within Indication:**
 - **Tepezza**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$350k (608%) to current \$58k.
 - Plan Cost Net PMPM ↑ \$2.46 (716.2%) to current \$2.80.
 - Patient Count: Remains at 1.
 - Adjusted Rxs ↑ 6 to current count of 7.

 - **Eylea**
 - Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$56k (148.3%) to current \$94k.
 - Plan Cost Net PMPM ↑ \$.42 (186.2%) to current \$.64.
 - Patient Count ↑ 3 to current count of 13.
 - Adjusted Rxs ↑ 30 to current count of 53.

 - **Other drug changes in this indication were not notable.**

- **Vaccinations:**
 - Previous ranked 5th, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↑ \$335k (54.1%) to current \$953k.
 - Plan Cost Net PMPM ↑ \$2.86 (77.6%) to current \$6.54.
 - Patient Count ↓ 1,852 to current count of 4,814.
 - Adjusted Rxs ↓ 2,418 to current count of 8,770.

- **Notable Drug Changes within Indication:**
 - **Comirnaty 2023-2024 (COVID):**
 - New, currently ranked 1st.
 - Plan Cost Net: New, current \$239k.
 - Plan Cost Net PMPM: New, current \$1.64.
 - Patient Count: New, current count of 1,701.
 - Adjusted Rxs: New, current count of 1,697.

 - **Spikevax 2023-2024 (COVID):**
 - New, currently ranked 2nd.
 - Plan Cost Net: New, current \$179k.
 - Plan Cost Net PMPM: New, current \$1.23.
 - Patient Count: New, current count of 1,193.
 - Adjusted Rxs: New, current count of 1,189.

 - **Arexvy (RSV):**
 - New, currently ranked 3rd.
 - Plan Cost Net: New, current \$132k.

- Plan Cost Net PMPM: New, current \$.91.
- Patient Count: New, current count of 493.
- Adjusted Rxs: New, current count of 490.

Peer Comparison:

- Peer: ESI CDH Program
- PEBP CDHP is outperforming the peer.
- Peer experienced Plan Cost Net PMPM of \$89.92 compared to CDHP PEBP of \$73.39.
- Peer experienced Trend of 13.0%, compared to CDHP PEBP Trend of 9.1%

EPO Overall Trend Summaries:

| EPO Overall Trend | % Change | |
|---|-----------------|--------------|
| Current Period - Plan Cost Net PMPM | \$168.02 | |
| Utilization | \$6.11 | 4.1% |
| Unit Cost | \$9.58 | 6.4% |
| Member Share | \$2.99 | 2.0% |
| Total Change in Plan Cost Net PMPM | \$18.68 | 12.5% |
| Previous Period - Plan Cost Net PMPM | \$149.33 | |

Top moving indications and most notable drug changes within the indications are as follows:

- **Endocrine Disorders:**
 - Previous ranked 3rd, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net ↑ \$190k (34.3%) to current \$742k.
 - Plan Cost Net PMPM ↑ \$7.29 (52.0%) to current \$21.33.
 - Patient Count ↓ 3 to current count of 25.
 - Adjusted Rxs ↓ 14 to current count of 107.
- **Notable Drug Changes within Indication:**
 - **Korlym:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$201k (40.2%) to current \$702k.
 - Plan Cost Net PMPM ↑ \$7.46 (40.2%) to current \$20.19.
 - Patient Count ↑ 1 to current count of 2.
 - Adjusted Rxs ↑ 5 to current count of 12.
 - **Other drug changes in this indication were not notable.**
- **Vaccinations:**
 - Previous ranked 5th, currently ranked 11th by Plan Cost Net.
 - Plan Cost Net ↑ \$97k (73.1%) to current \$231k.
 - Plan Cost Net PMPM ↑ \$3.25 (95.9%) to current \$6.63.
 - Patient Count ↓ 303 to current count of 1,201.
 - Adjusted Rxs ↓ 347 to current count of 2,158.

- **Notable Drug Changes within Indication:**
 - **Comirnaty 2023-2024 (COVID):**
 - New, currently ranked 1st.
 - Plan Cost Net: New, current \$60k.
 - Plan Cost Net PMPM: New, current \$1.73.
 - Patient Count: New, current count of 423.
 - Adjusted Rxs: New, current count of 423.
 - **Spikevax 2023-2024 (COVID):**
 - New, currently ranked 2nd.
 - Plan Cost Net: New, current \$46k.
 - Plan Cost Net PMPM: New, current \$1.31.
 - Patient Count: New, current count of 305.
 - Adjusted Rxs: New, current count of 305.
 - **Arexvy (RSV):**
 - New, currently ranked 3rd.
 - Plan Cost Net: New, current \$29k.
 - Plan Cost Net PMPM: New, current \$.82.
 - Patient Count: New, current count of 105.
 - Adjusted Rxs: New, current count of 105.
- **Skin Conditions:**
 - Previous ranked 7th, currently ranked 14th by Plan Cost Net.
 - Plan Cost Net ↓ \$73k (-39.3%) to current \$113k.
 - Plan Cost Net PMPM ↓ \$1.48 (-31.3%) to current \$3.26.
 - Patient Count ↓ 47 to current count of 287.
 - Adjusted Rxs ↓ 111 to current count of 455.
- **Notable Drug Changes within Indication:**
 - **Dupixent Pen:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↓ \$31k (-26.4%) to current \$86k.
 - Plan Cost Net PMPM ↓ \$.49 (-16.7%) to current \$2.46.
 - Patient Count ↓ 1 to current count of 9.
 - Adjusted Rxs ↓ 12 to current count of 40.
 - **Dupixent Syringe:**
 - Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↓ \$22k (-61.7%) to current \$14k.
 - Plan Cost Net PMPM ↓ \$.51 (-56.7%) to current \$.39.
 - Patient Count ↓ 1 to current count of 2.
 - Adjusted Rxs ↓ 9 to current count of 7.
 - **Other drug changes in this indication were not notable.**

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP EPO plan)
- The peer is outperforming PEBP EPO.
- Peer experienced Plan Cost Net PMPM of \$107.75 compared to PEBP EPO of \$168.02
- Peer experienced Trend of 10.3%, compared to PEBP EPO of 12.5%

PPO Overall Trend Summaries:

| PPO Overall Trend | | % Change |
|--|-----------------|--------------|
| Current Period - Plan Cost Net PMPM | \$100.05 | |
| Utilization | \$1.87 | 2.2% |
| Unit Cost | \$13.10 | 15.6% |
| Member Share | \$1.10 | 1.3% |
| Total Change in Plan Cost Net PMPM | \$16.07 | 19.1% |

Previous Period - Plan Cost Net PMPM **\$83.98**

Top moving indications and most notable drug changes within the indications are as follows:

- **Inflammatory Conditions:**

- Previous ranked 1st, currently ranked 1st by Plan Cost Net.
- Plan Cost Net ↑ \$826k (54.9%) to current \$2.3m.
- Plan Cost Net PMPM ↑ \$2.90 (16.1%) to current \$20.93.
- Patient Count ↑ 59 to current count of 222.
- Adjusted Rxs ↑ 404 to current count of 1,264.
- **Humira(CF) Pen:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$162k (34.0%) to current \$639k.
 - Plan Cost Net PMPM ↑ \$.02 (0.4%) to current \$5.74.
 - Patient Count ↑ 7 to current count of 31.
 - Adjusted Rxs ↑ 54 to current count of 163.
- **Stelara:**
 - Previous ranked 3rd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$169k (124.7%) to current \$304k.
 - Plan Cost Net PMPM ↑ \$1.11 (2.73%) to current \$2.73.
 - Patient Count ↑ 5 to current count of 11.
 - Adjusted Rxs ↑ 27 to current count of 62.
- **Rinvoq:**
 - Previous ranked 10th, currently ranked 5th by Plan Cost Net.
 - Plan Cost Net ↑ \$113k (211.1%) to current \$167k.
 - Plan Cost Net PMPM ↑ \$0.86 (133.1%) to current \$1.50.
 - Patient Count ↑ 8 to current count of 11.
 - Adjusted Rxs ↑ 37 to current count of 52.

- **Diabetes:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$750k (84.4%) to current \$1.6m.
 - Plan Cost Net PMPM ↑ \$4.07 (38.2%) to current \$14.71.
 - Patient Count ↑ 441 to current count of 1,222.
 - Adjusted Rxs ↑ 4,010 to current count of 11,098.
 - **Ozempic:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$263k (118.8%) to current \$485k.
 - Plan Cost Net PMPM ↑ \$1.70 (63.9%) to current \$4.35.
 - Patient Count ↑ 116 to current count of 240.
 - Adjusted Rxs ↑ 572 to current count of 1,107.
 - **Mounjaro:**
 - Previous ranked 5th, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$311k (776.5%) to current \$351k.
 - Plan Cost Net PMPM ↑ \$2.67 (556.9%) to current \$3.15.
 - Patient Count ↑ 105 to current count of 145.
 - Adjusted Rxs ↑ 648 to current count of 730.
 - **Other drug changes in this indication were not notable.**
- **Enzyme Deficiencies:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$529k (228.3%) to current \$761k.
 - Plan Cost Net PMPM ↑ \$4.06 (146.0%) to current \$6.84.
 - Patient Count ↑ 3 to current count of 5.
 - Adjusted Rxs ↑ 13 to current count of 22.
- **Notable Drug Changes within Indication:**
 - **Nexviazyme:**
 - New, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current \$417k.
 - Plan Cost Net PMPM: New, current \$3.74.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 6.
 - **Palynziq:**
 - New, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net: New, current \$73k.
 - Plan Cost Net PMPM: New, current \$0.65.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 5.
 - **Galafold:**
 - New, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net: New, current \$58k.
 - Plan Cost Net PMPM: New, current \$0.52.

- Patient Count: New, current count of 1.
- Adjusted Rxs: New, current count of 2.

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP PPO plan)
- PEBP PPO is outperforming the peer in Plan Cost Net, however PEBP PPO experienced a higher Trend.
- PEBP PPO experienced Plan Cost Net PMPM of \$91.51 compared to peer of \$99.80.
- Peer experienced Trend of 6.2%, compared to PEBP PPO of 12.9%.

| Total Overall Trend | % Change | |
|--|----------------|--------------|
| Current Period - Plan Cost Net PMPM | \$94.84 | |
| Utilization | \$1.98 | 2.4% |
| Unit Cost | \$7.82 | 9.4% |
| Member Share | \$1.86 | 2.2% |
| Total Change in Plan Cost Net PMPM | \$11.66 | 14.0% |

Previous Period - Plan Cost Net PMPM **\$83.18**

Summary of Total – Overall the main driver of Trend was Specialty Utilization driven by an increase of 15% in Specialty patients. This resulted in an 17.6% increase in Specialty Days of Therapy.

Trend was mitigated by increased rebates of 38.1%. This produced a negative Unit Cost Trend of (-5.5%) on Specialty drugs and reduced NonSpecialty Unit Cost Trend to 9.7%, combined is 9.4%.

Member Cost contributed to Trend on both Specialty and NonSpecialty drugs. This is due to increased Utilization on Specialty drugs and Drug Mix on NonSpecialty drugs. Primary driven by utilization of more expensive brand drugs.

Key Statistics:

| Nevada PEBP Total | | | |
|-------------------------------------|--------------|--------------|--------|
| Description | Q2 FY24 | Q2 FY23 | Change |
| Average Members per Month | 48,640 | 48,466 | 0.4% |
| Number of Unique patients | 31,239 | 32,695 | -4.5% |
| Members Utilizing the Benefit | 64.2% | 67.5% | -3.2 |
| Gross Cost/Adjusted Rx | \$138.66 | \$118.67 | 16.8% |
| Plan Spend | \$42,345,378 | \$34,810,187 | 21.6% |
| Rebates (estimated) | \$14,667,722 | \$10,620,859 | 38.1% |
| Plan Cost Net | \$27,677,656 | \$24,189,328 | 14.4% |
| Plan Cost Net PMPM | \$94.84 | \$83.18 | 14.0% |
| Non-Specialty Plan Cost Net PMPM | \$42.82 | \$36.85 | 16.2% |
| Specialty Plan Cost Net PMPM | \$52.02 | \$46.34 | 12.3% |
| Generic Fill Rate | 85.1% | 84.1% | 1.0 |
| 90 Day Utilization | 60.8% | 61.7% | -0.9 |
| Retail - Maintenance 90 Utilization | 28.4% | 30.0% | -1.6 |
| Home Delivery Utilization | 32.4% | 31.7% | 0.7 |
| Member Cost Net % | 24.2% | 25.7% | -1.5 |

END OF REPORT